Registered title, quoted from ClinicalTrials.gov
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 35 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 35
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
- Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
- Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
- Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
- Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
- Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
- Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
- Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
- Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
- Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteGeneral Hospital of Ningxia Medical University宁夏医科大学总医院YinchuanHospital page
- Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
- Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
- Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteJiangmen Central Hospital江门市中心医院JiangmenHospital page
- Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
- Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
- Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
- Study siteLinyi People's Hospital临沂市人民医院LinyiHospital page
- Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
- Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
- Study siteSecond Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第二医院HarbinHospital page
- Study siteSecond Affiliated Hospital of Zunyi Medical University遵义医科大学第二附属医院ZunyiHospital page
- Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
- Study siteShandong Provincial Hospital山东省立医院JinanHospital page
- Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
- Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
- Study siteTangdu Hospital空军军医大学唐都医院Xi'anHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07010263, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed small cell lung cancer.
Inclusion criterion 5
Documented limited-stage SCLC (Stage I-III SCLC [T any, N any, M0] according to the American Joint Committee on Cancer Staging Manual [AJCC Cancer Staging Manual, 8th Edition] or the Veterans Administration Lung Study Group (VALG) stage.
Inclusion criterion 6
Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.
Inclusion criterion 9
Toxicities from previous anti-tumor treatments have not resolved to grade 0 or 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or to the levels specified in inclusion/exclusion criteria, except for alopecia.
Exclusion criterion 2
Received major surgery within 28 days prior to the first dose of study drug, or expected to undergo major surgery during the study period within 28 days after the first dose of study drug.
Exclusion criterion 6
Prior treatments with systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration of the study drugs. Prior treatment with Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications within 1 weeks before the first administration of the study drugs.
Exclusion criterion 11
Subjects requiring systemic treatment with corticosteroids (>10mg/day prednisone or equivalent dose) or other immunosuppressive drugs within 14 days prior to the first dose of study drug.
Exclusion criterion 14
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Inclusion criterion 3
Histologically or cytological confirmed the presence of mixed small cell lung cancer or non-small cell lung cancer components.
Exclusion criterion 1
History of active malignant tumors within the previous 5 years.
Exclusion criterion 5
Pregnant or lactating women.
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07010263, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
Inclusion Criteria:
- The subjects voluntarily participated in the study with full informed consent and signed written informed consent form.
- Aged ≥18 years on day fo signing the informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy ≥ 3 months
- Histologically or cytologically confirmed small cell lung cancer.
- Documented limited-stage SCLC (Stage I-III SCLC [T any, N any, M0] according to the American Joint Committee on Cancer Staging Manual [AJCC Cancer Staging Manual, 8th Edition] or the Veterans Administration Lung Study Group (VALG) stage.
- Have Received concurrent chemoradiotherapy regimen as defined in protocol and have not progressed following concurrent chemoradiotherapy.
- Adequate organ function.
- Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.
Exclusion Criteria:
- Histologically or cytological confirmed the presence of mixed small cell lung cancer or non-small cell lung cancer components.
- Toxicities from previous anti-tumor treatments have not resolved to grade 0 or 1 based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or to the levels specified in inclusion/exclusion criteria, except for alopecia.
- Symptoms or signs of primary disease deterioration that the investigator judges clinically unacceptable, such as cachexia.
- Presence of pleural effusion, pericardial effusion, or ascites, which was clinically symptomatic or requiring frequent drainage.
- History of active malignant tumors within the previous 5 years.
- Received major surgery within 28 days prior to the first dose of study drug, or expected to undergo major surgery during the study period within 28 days after the first dose of study drug.
- Uncontrolled comorbidities, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, and other related diseases..
- Have serious neurological or mental illnesses, including dementia and epileptic seizures.
- Pregnant or lactating women.
- Have cardiovascular or cerebrovascular diseases or risk factors.
- Prior treatments with systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration of the study drugs. Prior treatment with Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications within 1 weeks before the first administration of the study drugs.
- Prior treatments targeting immune mechanisms, including, but not limited to, immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy.
- Prior treatments with anti-angiogenic therapy.
- Subjects requiring systemic treatment with corticosteroids (>10mg/day prednisone or equivalent dose) or other immunosuppressive drugs within 14 days prior to the first dose of study drug.
- Known history of severe hypersensitivity reactions to other monoclonal antibodies or with a known history of allergy or hypersensitivity reactions to any of study drugs or their components.
- Active autoimmune diseases that require systemic treatment within 2 years prior to the study, or autoimmune diseases that the investigator judges to be potentially recurrent or require planned treatment.
- Known interstitial lung disease or non infectious pneumonia, which currently has symptoms or requires systemic corticosteroid treatment in the past,or investigator juges may affect the toxicity assessment or management related to the study treatment.
- Known severe infection within 4 weeks prior to the first dose of study drug. Known active tuberculosis. Known active syphilis infection. Known history of immunodeficiency or positive HIV test results.
- .Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Active hepatitis B or active hepatitis C.
- Received a live vaccine within 30 days prior to the first dose of study drug, or planning to receive a live vaccine during the study period.
Quoted from ClinicalTrials.gov, NCT07010263, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07010263, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.